

SAMED | 17 NOV 2020


# Centre for Clinical Excellence

### Building a global clinical capability





# SURGICALS



### **Requirements to enable accurate claim reimbursement**





### **Discovery Health (DH) Price and product file custodian**

DH require specific information to maintaining product details and prices. This information is not received from Medikredit.



### **Newly registered NAPPI Codes**

Require the relevant price and product information to classify and price products accordingly

- Not automatically funded
- DH pricefile team will issue a template for completion once the NAPPI code is registered with Medikredit
  - ISEM and the Health Technology Assessment team assess new products and technologies entering the market for clinical appropriateness and cost effectiveness
  - ISEM will evaluate M2 products only



### To accurately reimburse claims, suppliers should update their Pricefiles annually with DH

- This ensures that our system is up to date with all your products and their prices
- Without the latest dated price claims could be processed incorrectly. This results in members incurring a short payment and an inconvenience to providers, such as pharmacies and doctors, who have to deal with these short payments.

### **Processes and Contact details**



Classification and listing on the DH Pricefile	PRICE_AND_PRODUCT_FILE@discovery.co.za
Surgical NAPPI queries and approvals	ISEM@discovery.co.za
Price increases/Pricefile updates	ISEM@discovery.co.za
New Health Technology Submission	CPUWatchList@discovery.co.za
Health Provider Queries	HEALTHPARTNERS@discovery.co.za




# HTA

### Health Technology Assessment Discovery Health

NIRI BHIMSAN

### Health Technology Assessment (HTA)

- The *systematic evaluation* of properties, effects, and/or impacts of health technology.
- Uses scientific evidence (EBM) to assess the quality, safety, efficacy,
  - effectiveness and cost-effectiveness
- Supports best practices
- Applied to many health interventions diagnostic tests, medical devices, implanted prostheses, medicines etc.





### Is it safe?

# Does it improve health outcomes?

### Is it cost-effective

### Is it affordable?

## **INNOVATION vs Incremental Benefit**



Innovation: Any combination of activities or technologies that break existing performance tradeoffs in the attainment of an outcome, in a manner that expands the realm of the possible. Defined in health care as providing "more for less"—more value, better outcomes, greater convenience, access and simplicity; all for less cost, complexity, and time required by the patient and the provider, in a way that expands what is currently possible.


### PROCESS

- 1. Quality and Quantity of clinical evidence
- 2. Critical Appraisal of literature
- 3. Clear unmet need?
- 4. Cost vs benefit
- 5. Data analysis scheme experience
- 6. Cost-effectiveness, Budget impact


Is the Scheme paying for Value? Is it affordable and Sustainable

### The HTA process for new technology






Discovery HTA Process – published in *SAMJ* 




### **Clinical filter**





### **Financial filter and Health Economics (HE)**







	-
-	1
_	

Section C: Clinical information			
Brief description of new technology			
Clinical indications for new technology			

#### **Please ensure that:**

- Clinical indications for the use of the technology are clear.
- Does the evidence that has been submitted support the indication/s being requested

#### Please list alternative therapies/existing comparators\* and costs




Figure 1: Drug-eluting Stent Evo

(\*A comparator is a product/treatment/technology currently available in South Africa that is regarded as the standard of care which performs the same purpose/function as this product.)

Product Name	Product description	Supplier/Distributor	

#### **COMPARATORS:**

- Standard of Care
- Even if the new technology is different – will it replace the SoC?
  - E.g. Bioresorbable





### Section D: Regulatory bodies

#### International registration

Indicate if this product has international registration. Please attach the certificate to this document where applicable

Country	Date of registration	Registered indication
USA (FDA)		
× *		
- ·		

- Type of Approval
- Provide details that have resulted in the FDA approval
- Delays process substantially as
  - information has to be requested.

# Clinical Evidence supporting this technology

Please attach full text documents such as meta-analysis, systematic reviews, randomized trials and/or other studies that indicate the effectiveness and safety of this product. Clinical evidence should be submitted with the highest level of evidence (e.g. Meta-analysis, RCT etc) at the beginning of this section.

#### For each clinical trial attached, please supply the following information

Trial (Author, title, publication reference)	, <b>Trial Design</b> (e.g. RCT, Cohort study, Case series etc)	Comparator	Sample size in each treatment group	Outcome measure (e.g. Re-intervention required, blood loss etc)	Effect size

- Start with your highest level of evidence
- Please don't submit animal trials/models
- Complete the table comprehensively
- Ensure that it ties back to the indications being applied for



### Case Study ROBOTIC SURGERY: Prostatectomies and TAVI

### **Valves**



alves		Health Medica
<section-header><section-header><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></section-header></section-header>	Does the evidence suppor the indication/s	
<ul> <li>CAPITAL EQUIPMENT</li> <li>Robotic costs exceed R25M</li> <li>Consumables cost per patient high</li> </ul>	Does the benefit warrant the cost?	2011
<b>2013 Procedure Costs</b> Open R85 000 (95% of procedures) Lap R120 000 (5% of procedures) Lowest likely cost ROBOT R150 000		Mechanical Valve ~R22 000 TAVI - R216 600 (2018 newer versions R300 000)

### **Challenges in the Clinical Evidence**

### 1. Lack of direct comparisons to relevant alternative

- Head-to-head trials often not available
- o Comparator in trials may not be relevant in our setting
- o Lack of well-designed comparator trials poses a significant problem


### 2. Measuring relevant costs and benefits

- Vary from country to country (transferability)
- Clinical practice may also vary

### 3. Lack of long-term follow-up

- Especially important depending on what the claim is or where the benefit in the outcome is expected (e.g. robotic surgery and cancer outcomes?)
- o Decision needed now can't wait until long-term data is available
- What does it mean in the current context? (can it be applied? Is this the clearer role for registry data?)


### 4. Superiority of Devices







### Considerations



CD: What are the main issues and challenges that typically face pharmaceutical and medical device companies during the litigation process? How might they go about addressing Vinnos . Department of Medicine Northwestern University Of Chicago, these issues?

Greenblatt: The disc

U.S. Department of Health and Human Services

5 takeaways amid new scrutiny of

FDA medical device oversight

Investigative Journalists.

A slate of FDA actions in recent days has paralleled release of investigative stories taking aim at regulators and manufacturers alife for lax safety

A slate of FDA actions in recent days has paralleled telease of interstient of a solution of a standards in a wide ranging probe by the International Consertion of standards, in a wide ranging probe by the International Consertion of standards, in a wide ranging probe by the International Consertion of standards. stories taking aim at regulators and manufacturers alike for har safety of stories taking aim at regulators and manufacturers alike for har safety of true at a vide-ranging probe by the International Consortium of standards, in a vide-ranging probe by the International Consortium of true attentive Journalists.

Food and Drug Administration

# Medical Reversal: Why We Must Raise the Bar LITIGATION IN THE PHARMACEUTICAL AND MEDICAL DEVICE SECTOR



#### he Bleeding Edge: behind the terrifying new Netflix documentary

The \$400bn medical device industry is exposed in a horrifying look at a string of products that have wreaked havoc on patients

S LAWSUITS FILED AGAINST MEDICAL DEVICE

One of these lawer it

New Jersey

years after receiving an inferior

manufactured by Cord

and lungs from

defecti

Multiple lawsuits have been filed against Cordis Corporation, a company based in Miami Lakes that nanufactures medical devices. According to these lawsuits, vascular filters manufactured by Cordis are prone to fracture, disintegration migration through the blood sustar

FDA Overlooked Red Flags In Drugmaker's Testing of New **Depression Medicine** 

ECTIVES

Vinay Prasad, MD, a and Adam Cifu, MD6.

Before Adopting New Technologies

INE 84 (2011), pp. 471-478.



## **CLINICAL POLICY**

Development of evidence based clinical funding policies that are credible, consistent and transparent to ensure access to quality, affordable and sustainable healthcare

LINDIWE PEMBA MBEKENI

### Agenda



- What constitutes policy
- What informs policy
- Considerations
- Challenges

### What constitutes policy



- Clinical funding policies / protocols
- Baskets of care
  - Consultations
  - Investigations pathology, radiology
  - Procedures
  - Allied therapies
- Medical supplies
  - Medicines formularies
  - Devices / surgical

### What informs policy



- Legislation
  - Medical Schemes Act
    - $\circ$  PMB defined
    - CDL algorithm
    - o DTPMB
  - Medicines and Related Substances Act
- Standard of care
  - Public sector vs private sector vs international
- Evidence HTA

- Guidelines
  - Current
  - Level of evidence EBM principles
  - Local, international
  - Strength of recommendation
  - Quality of the guideline
  - Where it is published
  - Societal vs other group(s)
  - AGREE, GRADE, SORT tools
- Societal recommendations

### **Considerations**



- Policies cover 80% of the population
- Regular review
  - Protocols annual
  - As required

### Challenges



- Local studies applicability of international references
- Guidelines EBM principles
- Website publication by clinician groups
- Legislation
  - Outdated
  - Stakeholder understanding







SAMED | 12 NOV 2020

# Centre for Clinical Excellence